Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Apr 19;4(2):12.
doi: 10.3390/vaccines4020012.

Recent Advances in Subunit Vaccine Carriers

Abhishek Vartak  1 , Steven J Sucheck  2
Affiliations
Review

Recent Advances in Subunit Vaccine Carriers

Abhishek Vartak et al. Vaccines (Basel). .

Abstract

The lower immunogenicity of synthetic subunit antigens, compared to live attenuated vaccines, is being addressed with improved vaccine carriers. Recent reports indicate that the physio-chemical properties of these carriers can be altered to achieve optimal antigen presentation, endosomal escape, particle bio-distribution, and cellular trafficking. The carriers can be modified with various antigens and ligands for dendritic cells targeting. They can also be modified with adjuvants, either covalently or entrapped in the matrix, to improve cellular and humoral immune responses against the antigen. As a result, these multi-functional carrier systems are being explored for use in active immunotherapy against cancer and infectious diseases. Advancing technology, improved analytical methods, and use of computational methodology have also contributed to the development of subunit vaccine carriers. This review details recent breakthroughs in the design of nano-particulate vaccine carriers, including liposomes, polymeric nanoparticles, and inorganic nanoparticles.

Keywords: liposomes; nanoparticles; polymeric nanoparticles; vaccines.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Variations with liposomal vaccine delivery system.
Figure 2
Figure 2
Polymers used in vaccine delivery.
See this image and copyright information in PMC

References

    1. Ragupathi G., Damani P., Srivastava G., Srivastava O., Sucheck S.J., Ichikawa Y., Livingston P.O. Synthesis of sialyl Lewisa (sLea, CA19-9) and construction of an immunogenic sLea vaccine. Cancer Immunol. Immunother. 2009;58:1397–1405. doi: 10.1007/s00262-008-0654-7. - DOI - PMC - PubMed
    1. Zhu J., Warren J.D., Danishefsky S.J. Synthetic carbohydrate-based anticancer vaccines: The memorial sloan-kettering experience. Expert Rev. Vaccines. 2009;8:1399–1413. doi: 10.1586/erv.09.95. - DOI - PMC - PubMed
    1. da Costa C., Walker B., Bonavia A. Tuberculosis vaccines—State of the art, and novel approaches to vaccine development. Int. J. Infect. Dis. 2015;32:5–12. doi: 10.1016/j.ijid.2014.11.026. - DOI - PubMed
    1. Fletcher H.A. Profiling the host immune response to tuberculosis vaccines. Vaccine. 2015;33:5313–5315. doi: 10.1016/j.vaccine.2015.07.090. - DOI - PubMed
    1. Tam P.H., Lowary T.L. Carbohydrate Chemistry: Chemical and Biological Approaches. Royal Society of Chemistry; London, UK: 2010. Mycobacterial lipoarabinomannan fragments as haptens for potential anti-tuberculosis vaccines; pp. 38–63.